Today: 21 May 2026
Browse Category

SWX:MIC 6 June 2025

Stock Market Today

  • Biocon's Earnings Hit by Share Dilution and Unusual Items Amid Flat Market Reaction
    May 20, 2026, 8:51 PM EDT. Biocon Limited (NSE:BIOCON) reported earnings down 62% last year, with earnings per share (EPS) falling 67%, revealing significant share dilution as the company issued 35% more shares. Despite a 17% annual profit decline over three years, market response was muted, indicating results met expectations. A ₹4.0 billion impact from unusual items also dampened profits but is unlikely to recur, potentially supporting a rebound next year. Investors should watch EPS closely, as rising net income without EPS growth may dilute shareholder value. Analysts' forecasts remain a key factor for assessing Biocon's future profitability and share price prospects.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop